HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Wells Fargo & Company reduced their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday. Barclays raised their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Truist Financial upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, December 13th. Finally, Jefferies Financial Group reduced their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Sangamo Therapeutics Stock Up 1.0 %

SGMO stock opened at $1.03 on Thursday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a market cap of $214.91 million, a PE ratio of -1.37 and a beta of 1.15. The business has a 50 day moving average of $2.14 and a 200 day moving average of $1.22.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the prior year, the business earned ($0.34) earnings per share. On average, research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $67,000. Meritage Portfolio Management lifted its holdings in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Sangamo Therapeutics in the 2nd quarter worth about $89,000. XTX Topco Ltd increased its position in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.